In addition to the integrated circuit design industry, Shanghai will also set up a M&A fund for the biomedical industry with a scale of 10 billion yuan.In this regard, Bu Rixin believes that "chain owners" enterprises, as market-oriented institutions, set up CVC funds and will carry out horizontal and vertical mergers and acquisitions around the upstream and downstream of key industrial chains. "This kind of M&A will help chain-owner enterprises to expand their market scale and enhance their market competitiveness, which is the most in line with the logic of M&A and the basic logic of the Action Plan to encourage chain-owner enterprises to set up CVC funds."Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.
Among them, Chengdu Ruiyuan Semiconductor is mainly engaged in the research and development, design, packaging and sales of power management chips, and one of its main products is DC/DC chips. A-share listed companies include Jingfeng Mingyuan, Fumanwei, Shanghai Beiling and Xidiwei, all of which have certain market share and competitiveness in the DC/DC chip market.However, in the field of large chips such as GPU, it has not yet run out of listed companies. It can be seen that Moore Thread, Biwa Technology, Suiyuan Technology, etc. have started the listing counseling process one after another.
Since then, after continuing to Shenzhen and Anhui, Shanghai has also made efforts in mergers and acquisitions.Bu Rixin said that only through mergers and acquisitions and accelerating industrial integration can the benign development of the industry be promoted, which is also one of the most effective measures.For the biomedical industry, Bu Rixin told the reporter of science and technology innovation board Daily that the investment cycle of biomedicine is generally long, and it needs to go through multiple stages from research and development to listing.